Loading
Every phase 2 or 3 interventional trial that was recruiting, about to open or still running for colorectal, colon or rectal cancer on ClinicalTrials.gov in September 2026, with the hospitals in the United Kingdom that take part named where the registry lists them.
The ClinicalTrials.gov v2 API was searched on 24 September 2026 for interventional phase 2, 1/2, 2/3 and 3 studies naming colorectal, colon or rectal cancer that were recruiting, not yet recruiting, enrolling by invitation or (for phase 3 and 2/3) active but closed to recruitment. Trials already in the corpus, and trials whose only bowel involvement is an anal, appendiceal, small-bowel or neuroendocrine condition, are left out; the remainder are carried here as registry-only records with no outcomes, because a trial that has not reported has no result to quote. Records link to the subtype page the registry text names (colon, rectum, MSI-high, BRAF V600E, HER2-amplified, KRAS G12C, early onset) and to `colorectal` itself only when it names none, so the cancer page stays under its markup ceiling. UK sites are quoted verbatim in each record's notes. The questions open today divide into four: whether circulating tumour DNA should choose who gets chemotherapy after surgery, whether the rectum can be kept after chemoradiotherapy or immunotherapy, whether targeted combinations (KRAS G12C, BRAF, HER2, RAS(ON)) belong in first-line treatment, and whether anything can make microsatellite-stable disease respond to immunotherapy.
Showing the technology this term belongs to: MRD / molecular residual disease testing.
Shares A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer, Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Co, Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression, Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR.
Shares A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer, An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis, Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer, COLLISION RELAPSE Trial.
Shares A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis, A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer, A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational, Adaptive Radiotherapy for Safe Hypofractionation.
Shares Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer, mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer, Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer, mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC.
Shares Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer, A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer, Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?, Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
Shares Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer, mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer, Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer, mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC.
Shares A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Meta, A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer, A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC, Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients.
Shares Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer, Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers, Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome, Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer.